• Norovirus Harnesses NINJ1 for Selective Intracellular Protei

  2026-05-15

  Song et al. reveal that murine norovirus co-opts the cell death effector NINJ1 to selectively secrete the viral NS1 protein, uncovering a regulated, unconventional pathway for protein export during infection. This discovery advances our understanding of host-pathogen interactions, apoptosis regulation, and the specificity of damage-associated molecular pattern release.

• Quantitative In Vitro Approaches Refine Cancer Drug Response

  2026-05-15

  Schwartz’s dissertation introduces a refined in vitro methodology that distinguishes between proliferative arrest and cell death in evaluating anti-cancer drug responses. This dual-metric framework enhances the precision of preclinical studies, supporting the rational development and mechanistic interrogation of targeted agents such as survivin inhibitors in oncology research.

• Sorafenib (SKU A3009): Reliable Multikinase Inhibition in Ca

  2026-05-14

  This article delivers a scenario-driven, evidence-based guide to using Sorafenib (SKU A3009) as a robust cancer biology research tool. Readers will find actionable insights on optimizing cell-based assays, interpreting proliferation data, and selecting reliable sources, all grounded in real-world laboratory needs and peer-reviewed data. The analysis underscores how Sorafenib’s validated potency and reproducibility make it a top choice for bench scientists.

• Structure–Function Insights: High-Throughput Discovery of RA

  2026-05-14

  This study presents a combinatorial, machine-learning-driven approach to develop cationic RAFT polymers optimized for mRNA delivery. The findings reveal key molecular features affecting transfection, cellular uptake, and cytotoxicity, offering actionable guidance for next-generation non-lipid mRNA delivery strategies.

• Indometacin Sodium in Modified Natural-Cycle IVF: RCT Insigh

  2026-05-13

  This article examines a randomized controlled trial assessing indometacin sodium's ability to prevent premature ovulation in modified natural-cycle IVF. The study reveals nuanced efficacy, with potential benefits in a specific patient subgroup, and highlights implications for anti-inflammatory research and reproductive medicine.

• Phillygenin Attenuates Diabetic Nephropathy via Inflammation

  2026-05-13

  This study identifies phillygenin as a potent inhibitor of inflammatory and apoptotic pathways in diabetic nephropathy. By targeting TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling, phillygenin improves renal function and reduces kidney injury in db/db mouse models, advancing molecular understanding and potential therapeutic strategies for diabetic nephropathy.

• Epinephrine Bitartrate: Strategic Leverage for Translational

  2026-05-12

  This thought-leadership article explores the mechanistic and strategic considerations for deploying (-)-Epinephrine (+)-bitartrate in translational research. We dissect its role as a non-selective adrenergic receptor agonist across cell signaling, cardiovascular, and neurobiological domains, while providing actionable protocol guidance and industry context. Drawing on recent evidence, including stewardship strategies during anesthetic shortages, we position APExBIO’s Epinephrine Bitartrate as a cornerstone for reproducible, high-impact studies, and offer a forward-looking perspective on optimizing resource use and experimental rigor.

• Isradipine (Dynacirc): Applied Workflows in Neurovascular Re

  2026-05-12

  Isradipine (Dynacirc) empowers researchers with selective L-type calcium channel blockade for reproducible insights in neuroprotection and vascular smooth muscle relaxation. This guide demystifies experimental workflows, troubleshooting, and evidence-backed protocol enhancements using APExBIO's high-purity Isradipine.

• Immune Cell Rejuvenation Reduces Alzheimer’s Pathology in Mi

  2026-05-11

  This study demonstrates that rejuvenating peripheral immune cells via young bone marrow transplantation in an Alzheimer’s mouse model ameliorates hallmark disease pathologies and behavioral deficits. The findings provide mechanistic insight and preclinical evidence for targeting immune aging as a therapeutic approach in neurodegeneration.

• X-Gal (A2539): Precision Substrate for Blue-White Screening

  2026-05-11

  X-Gal, also known as 5-bromo-4-chloro-indolyl-β-D-galactopyranoside, is a validated chromogenic substrate central to blue-white colony screening in molecular cloning. Its mechanism—yielding a blue precipitate upon β-galactosidase hydrolysis—enables robust, visual identification of recombinant DNA events. APExBIO’s X-Gal (A2539) offers high purity and reliable performance, supporting reproducible results in demanding molecular workflows.

• Human Milk L. reuteri FN041 Ameliorates DSS-Induced Colitis

  2026-05-10

  This study demonstrates that Limosilactobacillus reuteri FN041, isolated from human milk, significantly alleviates ulcerative colitis symptoms in a DSS-induced mouse model. By remodeling gut microbiota composition and restoring key metabolites, FN041 offers mechanistic insights into probiotic-based interventions for inflammatory bowel diseases.

• Digoxin as a Na+/K+ ATPase Pump Inhibitor: Lab Workflows & I

  2026-05-09

  Digoxin stands out as a dual-purpose Na+/K+ ATPase pump inhibitor, powering reproducible workflows in both cardiac contractility modulation and targeted antiviral research. This guide details protocol optimization, troubleshooting, and actionable insights based on high-purity Digoxin from APExBIO—empowering next-generation experimental design across cardiovascular and chikungunya virus models.

• D-N-Acetylgalactosamine: Technical Guidance for Brain Studie

  2026-05-09

  D-N-Acetylgalactosamine is a high-purity, water-soluble metabolite essential for studying glycoprotein structure and glycosylation in brain tissue. It should not be used in protocols requiring ethanol solubility or long-term storage of solutions. Researchers must follow handling and workflow recommendations to ensure experimental consistency.

• Vancomycin in Translational Microbiome Research: Mechanisms

  2026-05-08

  This thought-leadership article synthesizes mechanistic insight with strategic guidance for translational researchers leveraging Vancomycin, a glycopeptide antibiotic, in advanced microbiome and bacterial resistance studies. Drawing on recent evidence—including immunomodulation, microbiota engineering, and workflow best practices—we explore how APExBIO’s Vancomycin enables next-generation MRSA and Clostridium difficile research, while bridging the immune-microbiota interface. The piece expands beyond conventional product coverage by critically evaluating experimental design, cross-domain opportunities, and the evolving landscape of resistance mechanism investigation.

• NSAID Cytotoxicity in Canine Osteosarcoma: Insights for Bone

  2026-05-07

  This study systematically evaluated deracoxib and piroxicam for their in vitro cytotoxic effects on canine osteosarcoma cell lines, revealing that only high concentrations reduced cell viability without inducing apoptosis. The findings provide a benchmark for antiproliferative assay design and highlight the need for more selective agents in bone tumor research.

451 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page